Drug Profile
Research programme: small molecule therapeutics - Odyssey Thera/Pfizer
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Odyssey Thera
- Developer Odyssey Thera; Pfizer
- Class Small molecules
- Mechanism of Action Protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 08 Oct 2009 Preclinical development is ongoing in the USA